PMC:7195088 / 27648-27898 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T138","span":{"begin":154,"end":162},"obj":"Disease"}],"attributes":[{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ase fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Prim"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T149","span":{"begin":29,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T150","span":{"begin":74,"end":76},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"}],"text":"ase fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Prim"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T368","span":{"begin":101,"end":119},"obj":"Chemical"}],"attributes":[{"id":"A368","pred":"chebi_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"ase fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Prim"}

{"project":"LitCovid-sentences","denotations":[{"id":"T207","span":{"begin":85,"end":193},"obj":"Sentence"},{"id":"T208","span":{"begin":194,"end":245},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ase fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Prim"}